Repositioning Candidate Details
| Candidate ID: | R1053 |
| Source ID: | DB06599 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Lexatumumab |
| Synonyms: | Lexatumumab |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Lexatumumab is a fully humanized, high-affinity immunoglobulin G(1 lambda) monoclonal antibody (mAb). |
| CAS Number: | 845816-02-6 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in cancer/tumors (unspecified). |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Lexatumumab agonizes the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAIL-R2), triggering the extrinsic apoptotic pathway. |
| Targets: | Tumor necrosis factor receptor superfamily member 10B |
| Inclusion Criteria: | Therapeutic strategy associated |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|